| Literature DB >> 29046793 |
Senji Hoshi1,2, Kenji Numahata1, Hidenori Kanno1, Masahiko Sato1, Akihito Kuromoto1, Kunihisa Nezu1, Takanari Sakai1, Chihito Konno3, Yuichi Ishizuka3, Hideaki Izumi3, Katsuyuki Taguchi3, Kunio Ono3, Kiyotsugu Hoshi2, Satoshi Kanto2, Rika Takahashi4, Bilim Vladimir5, Naoe Akimoto6, Isoji Sasagawa2, Shoichiro Ohta6.
Abstract
Molecular-targeted therapy was recommended for the systemic therapy of renal cell cancer (RCC) in the RCC guidelines, but these guidelines do not address the order of administration of the multiple presently available agents. There are several aspects that remain unknown regarding the optimal administration order and combination of molecular-targeted drugs. Until the optimal treatment sequence is determined by clinical trials, treatment individualization is required for each patient based on patient and disease characteristics. We herein investigate 12 cases of RCC patients who received axitinib. Axitinib was used as the first-line drug in 4 cases, second-line in 5 cases, third-line in 1 case and as a fourth-line drug in 2 cases. Partial response (PR) was observed in 4 cases (30%) and stable disease in 4 cases (30%) during axitinib treatment, with an overall response rate of 60%. The duration of PR ranged from 6 to 19 months. Based on our cases, axitinib exhibited reasonable therapeutic efficacy as first- as well as second-line treatment. However, more cases are required to draw firm conclusions.Entities:
Keywords: axitinib; renal cancer; tyrosine kinase inhibitor
Year: 2017 PMID： 29046793 PMCID： PMC5639413 DOI： 10.3892/mco.2017.1371
Source DB: PubMed Journal: Mol Clin Oncol ISSN： 2049-9450